Canada Markets open in 32 mins

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.7600-0.0100 (-0.36%)
At close: 4:00PM EDT
2.7201 -0.04 (-1.45%)
Pre-Market: 08:49AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.7700
Open2.7100
Bid2.7000 x 1000
Ask2.7600 x 1000
Day's Range2.6200 - 2.7800
52 Week Range2.2300 - 6.8800
Volume874,115
Avg. Volume569,060
Market Cap121.954M
Beta (5Y Monthly)0.46
PE Ratio (TTM)N/A
EPS (TTM)-1.3100
Earnings DateOct. 27, 2021 - Nov. 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.24
  • GlobeNewswire

    InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19

    Initial portion of the grant amounts to EUR 25.8 millionRemainder of the grant will be awarded in three additional milestone-dependent tranches JENA, Germany, Oct. 19, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that the German Ministry of Education and Research (“Bundesministerium für Bildung und Forschung“ or “BMBF“) and the German Ministry of Healt

  • GlobeNewswire

    InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19

    Study has enrolled 369 patients across 9 countriesTopline results expected to be available in Q1 2022 JENA, Germany, Oct. 12, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the completion of enrollment of the Phase III part of the Phase II/III vilobelimab study in severe COVID-19 patients. The randomized, double-blind and placebo-controlled Phase III par

  • GlobeNewswire

    InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    JENA, Germany, Sept. 09, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces that Prof. Niels C. Riedemann, Chief Executive Officer and Founder, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually. The presentation will be available on demand starting at 7:00 AM EDT / 1:00 PM CET on Monday, Septe